Johnson & Johnson (NYSE:JNJ - Free Report) - Investment analysts at Leerink Partnrs dropped their Q3 2025 earnings estimates for Johnson & Johnson in a research note issued to investors on Thursday, July 17th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $2.65 per share for the quarter, down from their prior forecast of $2.74. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Leerink Partnrs also issued estimates for Johnson & Johnson's Q4 2025 earnings at $2.68 EPS, FY2025 earnings at $10.87 EPS, FY2026 earnings at $11.42 EPS, FY2027 earnings at $12.30 EPS and FY2029 earnings at $14.88 EPS.
Other research analysts also recently issued research reports about the company. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $174.11.
View Our Latest Analysis on JNJ
Johnson & Johnson Price Performance
NYSE JNJ traded up $0.67 during midday trading on Friday, hitting $163.65. The company had a trading volume of 9,764,459 shares, compared to its average volume of 8,138,164. The company has a market capitalization of $393.75 billion, a PE ratio of 17.50, a P/E/G ratio of 2.18 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average price of $154.10 and a 200-day moving average price of $154.84.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.82 earnings per share.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Lantz Financial LLC boosted its holdings in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. bought a new position in Johnson & Johnson during the fourth quarter worth $453,000. Joel Isaacson & Co. LLC grew its holdings in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares during the period. State of Wyoming increased its stake in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC raised its holdings in shares of Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the period. 69.55% of the stock is owned by institutional investors.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.18%. Johnson & Johnson's payout ratio is 55.61%.
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
